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Abstract. We studied effects of combined diethylcarbamazine (DEC) and albendazole (ALB) treatment on
Wuchereria bancrofti microfilaria (MF) uptake and development of infective larvae (L3) in Culex pipiens. Consenting
Egyptian adults with microfilaremia (MF > 300/mL) were treated with one or seven daily doses of DEC/ALB. Labo-
ratory-reared mosquitoes were fed on subjects before and after treatment. MF uptake and infectivity (assessed by
mosquito dissection) were reduced by 89.6% and 82.9%, respectively, 12 months after single-dose treatment and by
96.2% and 99.7%, respectively, after multi-dose treatment. The L3:mosquito ratio decreased by 88% to 0.082 after
single-dose treatment and by 99.8% to 0.001 after multi-dose treatment. If high coverage rates can be achieved for
several annual cycles, mass drug administration (MDA) with DEC/ALB has the potential to decrease transmission to
unsustainable levels and eliminate filariasis in populations. Multi-dose MDA (especially in the first year) might interrupt
transmission with fewer cycles than single-dose treatment.
INTRODUCTION
Lymphatic filariasis (LF) is a serious, mosquito-borne ill-
ness that affects some 120 million people in 80 countries;
more than one billion people reside in endemic areas and are
at risk of becoming infected with the nematode parasites that
cause LF (Wuchereria bancrofti, Brugia malayi, and B.
timori).1 Several features of LF make this disease a good
candidate for global elimination. First, there is no significant
animal reservoir, and the infecting organisms cannot survive
outside of their human and mosquito hosts. Second, the in-
fection is inefficiently transmitted; many infective bites are
required to establish new infections. Third, improved diag-
nostic tests have greatly simplified the process of identifying
and mapping endemic areas.2 Fourth, there are now single-
dose oral treatments that safely and effectively reduce mi-
crofilaria (MF) counts to very low levels.3,4 Based on these
and other considerations, the World Health Assembly
adopted a resolution calling for global elimination of LF as a
public health problem by the year 2020, and this resolution
led to launching of the Global Program for Elimination of
Lymphatic Filariasis (GPELF) in 2000.1,5 This program is
based on the premise that mass administration of antifilarial
medications (mass drug administration or MDA) can reduce
the reservoir of MF to levels that cannot sustain transmission
of the infection. In practice, national filariasis elimination
programs generally aim to treat at least 80% of endemic
populations with a single-dose of treatment annually for five
years. Available treatments are only partly effective against
adult filarial worms, which are believed to live for 5–7 years.
Therefore, the five-year duration for MDA programs was
chosen to minimize chances for adult parasites to survive
MDA and renew the reservoir of MF in human populations
needed for re-establishment of transmission. Repeated cycles
of MDA also increase the percentage of endemic populations
that receive any treatment, which further reduces availability
of MF for transmission.
The recommended annual regimen for MDA in areas with-
out coexisting onchocerciasis or loiasis is a single dose of
diethylcarbamazine citrate (DEC) plus albendazole (ALB).
This regimen is clinically safe and well tolerated, and it re-
duces levels of W. bancrofti MF for up to two years post-
treatment.3,4,6,7 However, prior studies have shown that low-
level residual microfilaremia persists in most patients after a
single dose of DEC/ALB.4 The impact of this treatment on
parasite uptake and development by mosquitoes has not been
previously studied.
Bancroftian filariasis is focally endemic in Egypt, and the
population at risk has been estimated to be approximately
two million.8 The principal vector responsible for transmis-
sion of filariasis in Egypt is Culex pipiens pipiens.9 Culicines
are relatively efficient vectors of W. bancrofti.10 The thresh-
olds for MF prevalence and MF counts in blood necessary for
transmission by culicines are largely unknown. We have re-
cently reported that only about one-third of W. bancrofti MF
ingested by Cx. pipiens mature to the infective stage (L3).11
We found that while Cx. pipiens sometimes ingest MF when
they feed on infected subjects with negative 50 L thick blood
smears, such feedings produce very few L3. That study also
showed that single-dose DEC treatment of MF carriers dra-
matically decreased MF uptake and L3 development in Cx.
pipiens. When one considers that GPELF (which calls for
delivery of MDA to millions of people in scores of countries)
is based on the premise that MDA will interrupt transmission
of filariasis, it is surprising that there are no published data on
the effects of combination treatment regimens recommended
by GPELF on parameters of transmission by vector mosqui-
toes. Therefore, the present study was designed to investigate
effects of combined DEC and ALB treatment of subjects with
bancroftian filariasis on MF uptake and L3 development in
Cx. pipiens. We have also compared effects of single-dose and
multi-dose treatments on these parameters.
MATERIALS AND METHODS
Selection of W. bancrofti-infected subjects. Human sub-
jects for mosquito studies were recruited from a two-arm
clinical treatment trial carried out by our team as previously
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described.12 Eligible subjects (healthy adult MF carriers with
at least 80 MF/mL of venous blood) were treated with one
oral dose of 6 mg/kg of DEC (Pharmamed Ltd., Zejtun,
Malta) and 400 mg of ALB (Zentel; GlaxoSmithKline, Ux-
bridge, United Kingdom) or seven daily doses of the same
combined regimen. None of these subjects had received anti-
filarial therapy for at least one year prior to the initiation of
the trial. Study subjects were assigned to treatment groups by
stratified randomization; strata used were MF/ML counts,
sex, and age. One subject in the multi-dose treatment group
received a single dose of DEC with ALB approximately one
month following the study treatment during a government
mass treatment program. This did not materially affect our
results, and we have elected to include data from this indi-
vidual in this report (intention to treat analysis).
Mosquito exposure to W. bancrofti carriers. Mosquito
feeding studies were performed 2–3 weeks before treatment
and repeated 3, 6, 9, and 12 months after treatment. Culex
pipiens pupae were collected from natural breeding sites in
Qalubiya Governorate and transported to an indoor insectary
with controlled temperature (26 ± 2°C), relative humidity 
70–80%, and a 16:8 photoperiod. Emerging mosquitoes were
maintained on a 10% sugar solution until 24 hours before
blood feeding. Three-to-five day old mosquitoes (approxi-
mately 200 females) were transported at night in a 30 × 30 ×
30 cm mesh-screened wooden cage to the field site for expo-
sure to MF carriers. The selected volunteer was asked to rest
for 30 minutes and then introduce his forearm into the cage
for another 30 minutes. To coincide with the periodicity of the
parasite, blood meals were offered to mosquitoes for 30 min-
utes between 10:00 PM and midnight. A finger prick thick
blood film (50 L) was prepared immediately prior to mos-
quito feeding for later staining with Giemsa and microscopic
examination.
Measurement of mosquito vector competence. For MF up-
take studies, an aliquot of blood-engorged females were cold-
killed immediately after feeding and stored at −70°C. Later,
ingested blood meals were thawed, dissected onto glass slides,
lysed in tap water, and microscopically examined for the pres-
ence and number of MF. Microfilaria uptake rates (percent-
age of mosquitoes with MF) and infection intensities (MF/
mosquito) were recorded.
To assess the development of L3 in mosquitoes, other
blood-fed females were maintained on a carbohydrate diet for
13 days (the extrinsic incubation period for W. bancrofti in
these mosquitoes in our insectary), dissected, and microscopi-
cally examined for the presence and number of L3. The in-
fectivity rate (percentage of mosquitoes with L3) and L3/
mosquito were recorded. The L3 yield was calculated for
mosquitoes fed on each donor, and defined as L3/mosquito
divided by MF/mosquito. Yield was not calculated in cases
with no MF ingested. Yield was assigned a value of 1.00 when
L3/mosquito was greater than MF/mosquito. Laboratory staff
responsible for dissections and entomologists evaluating the
effects of the treatments were unaware of treatment group
assignments for the human subjects.
The efficacy of the treatment regimens at each time point
was assessed three ways. The first was by changes in absolute
numbers of blood smear MF counts and parameters of mos-
quito vector competence. The second was by changes in blood
smear MF counts and parameters of mosquito vector compe-
tence relative to pre-treatment values. Relative values were
calculated for each subject by dividing post-treatment values
by pre-treatment values and multiplying by 100. In cases
where MF counts, MF uptake or infectivity increased after
treatment, relative values were considered to be 100% (i.e.,
no reduction). The third was by clearance rates for MF
counts, MF uptake, or infectivity, which were defined as the
percentages of treated subjects with negative blood smears,
who failed to transmit MF to blood-fed mosquitoes, or who
failed to generate infective mosquitoes, respectively. The pri-
mary endpoints for group comparisons in this study were pre-
defined to be complete absence of MF uptake and absence of
infective larvae in mosquitoes 13 days after feeding. Second-
ary endpoints were percentage reductions in MF uptake and
L3 production relative to pre-treatment values.
Ethical clearance. This study was reviewed and approved
by institutional review boards at Washington University
School of Medicine and at Ain Shams University. Written
informed consent was obtained from all subjects enrolled in
the study.
Data analysis. Database management and analysis were
performed with SPSS 11.1 software (SPSS Science, Chicago,
IL). The significance of differences in proportions was tested
by chi-square or Fisher’s exact tests. The Mann-Whitney U
test for nonparametric data was used to analyze differences
between independent group means of MF counts (thick
smear), percentages of MF uptake, and L3 infectivity, MF/
mosquito, and L3/mosquito. Paired comparisons over time of
absolute numbers of MF counts, rates and intensities of MF
uptake, and infectivity within each treatment group were per-
formed by the nonparametric Wilcoxon signed ranks test. Er-
ror values shown are SD except as noted. Correlations be-
tween variables were assessed by computing Spearman’s (rs).
RESULTS
Twenty-nine subjects were enrolled in the study. The two
treatment groups were comparable in terms of pre-treatment
filter MF counts by membrane filtration, sex ratio, and age (P
 0.727, P  0.812, and P  0.983, respectively) (Table 1).
In addition, subjects in the two treatment groups had compa-
rable MF counts by smear immediately before exposure to
mosquitoes (Table 2). A total of 4,084 mosquito blood meals
TABLE 1
Pre-treatment characteristics of Wuchereria bancrofti–infected subjects treated with either single- or multi-dose diethylcarbamazine
and albendazole
Treatment No. studied
Microfilaria/mL
Male:female*
Age (years)
Range Mean ± SD* Median Range Mean ± SD* Median
Single-dose 14 453–3,720 1,051.9 ± 843.8 747.5 9:5 18–67 35.0 ± 17.9 24.5
Multi-dose 15 340–4,531 1,064.0 ± 1,047.7 717.0 9:6 18–42 30.3 ± 8.2 31.0
* P > 0.05 for differences between treatment groups by Mann-Whitney test for means and chi-square test for proportions.
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from 137 feeds were dissected for MF uptake, with 29.8 ± 6.7
(median  30) females dissected per feed. Likewise, 18,780
females were dissected for infectivity, with 137.1 ± 82.9 mos-
quitoes dissected per feed (median  112). Pre-treatment
rates and intensities of MF uptake and infectivity for mosqui-
toes did not vary significantly between treatment groups
(Table 2).
Relationships between blood microfilaremia and param-
eters of W. bancrofti infection in mosquitoes. Before treat-
ment, rates of MF uptake (Figure 1A) and infectivity (Figure
1B) were significantly correlated with MF counts in thick
blood smears. There was a tendency for yield to increase with
lower MF counts (pre-treatment data), but this tendency was
not statistically significant. Uptake of MF by mosquitoes re-
mained highly correlated with MF counts in blood smears at
all time points after treatment (rs 0.68, P < 0.001). Mosquito
infectivity was moderately correlated three months after
therapy (rs  0.45, P < 0.014), but this correlation became
stronger at later time points (rs  0.66, P < 0.001).
The L3 yield data were calculated for all subjects with posi-
tive MF smears (both groups combined). The L3 yields at 0,
3, 6, 9, and 12 months were 0.44 ± 0.28, 0.14 ± 0.24, 0.55 ± 0.44,
0.66 ± 0.35, and 0.55 ± 0.47, respectively. The decrease in yield
between times 0 and 3 months is significant (P  0.001); this
may reflect a temporary post-treatment effect on MF. The L3
yields were not significantly correlated with smear MF counts
before treatment or three months after treatment (rs −0.17,
P  0.384 and rs  0.20, P  0.540, respectively). However,
at all later time points, when MF counts in blood smears were
reduced, yields were significantly correlated with smear MF
counts (P  0.05).
Effects of treatment on blood MF counts, MF uptake, and
infectivity in mosquitoes. Absolute and relative data are
shown in Table 2 and Figure 2, respectively. Changes over
time within and between groups are more easily seen in Fig-
TABLE 2
Wuchereria bancrofti infection* in human subjects and in blood-fed Culex pipiens before and after treatment with single- or multi-dose dieth-
ylcarbamazine and albendazole
Time† No.* MF/50 L
Infection rates (%) Infection intensity
MF uptake Infectivity MF/100 mosquitoes L3/100 mosquitoes
Pre-treatment
Single-dose 14 49.9 ± 23.2 49.8 ± 20.4 33.9 ± 15.1 195.9 ± 169.4 66.8 ± 47.7
Multi-dose 15 42.7 ± 43.5 52.4 ± 25.2 30.5 ± 15.9 255.5 ± 3.454 64.0 ± 47.7
P‡ 0.138 0.827 0.600 0.827 0.861
3 months post-treatment
Single-dose 14 25.1 ± 38.2 20.9 ± 20.6 3.1 ± 4.2 44.2 ± 46.1 6.2 ± 9.2
Multi-dose 15 1.1 ± 2.1 0.8 ± 3.1 0.0 ± 0.0 2.0 ± 7.8 0.0 ± 0.0
P‡ 0.000 0.000 0.002 0.000 0.002
6 months post-treatment
Single-dose 14 17.0 ± 22.7 12.8 ± 14.0 12.5 ± 14.4 19.6 ± 25.2 24.2 ± 32.5
Multi-dose 12 1.9 ± 5.4 1.1 ± 1.9 0.8 ± 1.3 1.3 ± 1.9 1.0 ± 2.0
P‡ 0.005 0.005 0.004 0.006 0.004
9 months post-treatment
Single-dose 14 11.7 ± 16.1 11.7 ± 13.9 7.8 ± 9.8 16.0 ± 22.6 14.0 ± 20.7
Multi-dose 13 1.2 ± 3.6 0.2 ± 0.7 0.2 ± 0.6 0.2 ± 0.6 0.2 ± 0.6
P‡ 0.002 0.000 0.002 0.000 0.002
12 months post-treatment
Single-dose 14 9.9 ± 14.2 5.2 ± 7.9 5.8 ± 6.9 6.1 ± 10.5 8.2 ± 10.9
Multi-dose 12 0.3 ± 0.5 2.0 ± 3.7 0.09 ± 0.2 2.0 ± 3.7 0.1 ± 0.2
P‡ 0.012 0.317 0.002 0.317 0.002
* Data shown are means ± SD. No.  number of human subjects tested; MF  microfilaria; L3  infective larvae.
† All post-treatment values in both treatment groups were significantly lower than pre-treatment values (P  0.009 and P  0.003, by analysis of variance for the single-dose and multi-dose
treatment groups, respectively).
‡ The Mann-Whitney U test was used for group comparisons.
FIGURE 1. Relationships between night blood microfilaria (MF)
counts by thick smear in human subjects and MF uptake rates (A)
and infectivity rates (B) in Culex pipiens fed on these subjects. Spear-
man’s rs for MF count versus MF uptake rate, MF count versus
infectivity rate, and MF uptake rate versus infectivity rate were 0.84,
0.79, and 0.81, respectively.
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ure 2, which plots data relative to pre-treatment values. Fol-
lowing DEC/ALB treatment, both treatment groups showed
substantial reductions in all parameters. However, multi-dose
treatment was more effective than single-dose treatment in
reducing all parameters at all times until 12 months after
treatment, when differences in MF uptake and MF/mosquito
were not significant. Note that relative infectivity in the
single-dose treatment group was significantly lower three
months after treatment than at later time points. By the 12-
month time point, relative infectivity rates were 15.2 ± 17.6
and 0.3 ± 0.7% of pre-treatment values for the single-dose
and multi-dose treatment groups, respectively.
Poor (or delayed) responses to treatment. Responses to
treatment were somewhat variable in different subjects. We
considered subjects whose MF counts, MF uptake, or infec-
tivity decreased by < 50% relative to pre-treatment values to
be poor responders (Table 3). There were more poor re-
sponders in the single-dose treatment group, but this differ-
ence decreased over time. Most poor responses were only
temporary. That is to say, they were actually delayed re-
sponses to treatment. Only one of 26 people studied in either
group was a poor responder 12 months after treatment. This
person (a 24-year-old man who was a single-dose treatment
recipient) had pre-treatment MF counts of 45 per 50 L and
1,375 per mL by thick smear and membrane filtration, respec-
tively. His MF counts 12 months post-treatment were 48 per
50 L by smear and 264 per mL by filter. The reduction by
filter was 81%. Thus, it is likely that his pre-treatment MF
count by smear was spuriously low. Infectivity values for this
subject were 28.5% before treatment and 17.0% at 12 months.
Thus, although his MF count (by membrane filtration) de-
creased after treatment, his residual microfilaremia at 12
months was sufficient to give him a poor response regarding
infectivity.
Clearance rates. Clearance data strongly favor the multi-
dose treatment group (Table 4). However, neither treatment
regimen completely cleared blood MF, MF uptake, or L3 de-
velopment in all subjects. Complete clearance of infectivity was
transiently observed three months after multi-dose treatment.
Vector competence of mosquitoes fed on MF smear-
positive and smear-negative subjects. Table 5 compares vec-
tor competence data obtained from subjects with positive and
negative MF smears after treatment, regardless of treatment
group. Rates and intensities of MF uptake by mosquitoes for
smear-negative subjects were significantly lower than those
for smear-positive subjects at all time points after therapy
with DEC/ALB. Infectivity and L3/mosquito were also sig-
nificantly lower in mosquitoes fed on smear-negative subjects
at all time points except three months post-treatment. Indeed,
very few L3 were recovered from mosquitoes fed on smear-
negative subjects.
FIGURE 2. Changes in various parameters following single-dose () or multi-dose () treatment of human subjects with diethylcarbamazine and
albendazole. Data points (mean and SE) are shown as percentages relative to pre-treatment values for night blood microfilaria (MF) counts by
thick smear (A), MF uptake rates (B), MF per mosquito (C), infectivity rates (D), and infective larvae (L3) per mosquito (E).
TABLE 3
Number of poor (or delayed) responses* to treatment with single- or
multi-dose diethylcarbamazine and albendazole
Time
post-treatment
No. of
subjects tested Smear MF uptake Infectivity
3 months
Single-dose 14 3 4 0
Multi-dose 15 1 0 0
6 months
Single-dose 14 2 3 5
Multi-dose 12 1 1 0
9 months
Single-dose 14 1 2 1
Multi-dose 13 0 0 0
12 months
Single-dose 14 1 0 1
Multi-dose 12 0 0 0
* Subjects with poor (or delayed) responses to treatment had < 50% reductions in mi-
crofilaria (MF) count by thick smear, MF uptake rate, and/or infectivity rate (relative to
pre-treatment values).
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DISCUSSION
We have previously reported effects of therapy with single-
dose DEC on MF uptake and L3 production in Cx. pipiens.11
The present project studied people with higher MF counts
who were treated with two different DEC/ALB treatment
regimens; subjects were restudied on multiple occasions over
12 months following treatment. A number of groups have
reported effects of DEC/ALB on microfilaremia and adult
worms in bancroftian filariasis.3,4,12–17 However, this is the
first study of the impact of DEC/ALB on MF uptake and L3
production by mosquitoes.
The relationships between MF counts in blood smears and
MF uptake or infectivity observed prior to treatment in this
study were consistent with results in our previous study.11 The
L3 yield prior to treatment was slightly higher in this study
(0.44) than in our previous study (0.29). The low L3 yield
three months after treatment suggests the possibility that
DEC/ALB had a post-treatment effect on MF that impaired
their ability to survive or develop in mosquitoes. This effect
did not persist at later time points. Indeed, increased yield
values observed at 6–12 months after treatment may reflect
very low MF counts at those time points. This would be con-
sistent with limitation, as previously observed in Cx. pipi-
ens.10,18–21 This tendency toward increased efficiency of L3
production at low MF counts would tend to make it more
difficult to interrupt filariasis transmission in areas with Culex
transmission.
Treatment with single-dose DEC/ALB induced dramatic
and sustained reductions in blood MF counts and parameters
of mosquito infection that lasted for at least one year after
treatment. Although single-dose treatment did not com-
pletely clear MF from human blood or totally block MF up-
take and infectivity in mosquitoes in most cases, it is quite
possible that multiple cycles of this treatment will be suffi-
cient to eliminate filariasis transmission in disease-endemic
areas such as Egypt. Indeed, we have previously suggested
that repeated MDA with DEC alone might be sufficient to
interrupt transmission in areas such as Egypt with low base-
line infection prevalence rates and intensities.11,22,23
Multi-dose DEC/ALB treatment was significantly more ef-
fective than single-dose treatment in suppressing and sustain-
ing reductions in MF in blood smears and MF uptake and
development in mosquitoes. This was true at almost all time
points, whether one looks at absolute numbers, relative re-
ductions, or total clearance rates.
Our study identified a group of relatively poor or delayed
responders to DEC/ALB treatment. Most of these people
were in the single-dose treatment group, and most turned out
to be just delayed or late responders. Only one subject was
classified as a poor responder 12 months after treatment, and
this subject showed a good reduction in MF counts by mem-
brane filtration. Thus, there was no significant evidence of
resistance to DEC/ALB in the present study. Larger studies
and ongoing surveillance will be needed to look for emer-
gence of resistance to DEC/ALB as GPELF progresses.
TABLE 5
Wuchereria bancrofti infection of Culex pipiens fed on subjects with microfilaria (MF)–positive or –negative blood smears following diethylcar-
bamazine and albendazole treatment*
Mosquito infection
Months
post-treatment
Smear-positive
(no.) mean ± SD
Smear-negative
(no.) mean ± SD P†
% MF uptake 3 (18) 15.0 ± 19.5 (11) 3.3 ± 10.8 0.016
6 (15) 12.5 ± 13.5 (11) 0.6 ± 1.4 < 0.001
9 (13) 11.6 ± 14.6 (14) 1.1 ± 2.7 0.006
12 (12) 7.2 ± 7.8 (14) 0.7 ± 2.7 0.003
MF/100 mosquitoes 3 (18) 30.7 ± 41.8 (11) 8.7 ± 29.0 0.016
6 (15) 18.8 ± 24.4 (11) 0.6 ± 1.4 < 0.001
9 (13) 16.2 ± 23.6 (14) 1.1 ± 2.7 0.006
12 (12) 8.3 ± 10.5 (14) 0.7 ± 2.7 0.003
% infectivity 3 (18) 1.7 ± 2.8 (11) 1.2 ± 4.0 0.209
6 (15) 11.9 ± 14.1 (11) 0.5 ± 1.2 0.001
9 (13) 8.0 ± 10.2 (14) 0.6 ± 1.3 0.005
12 (12) 6.7 ± 7.2 (14) 0.2 ± 0.4 0.001
L3/100 mosquitoes 3 (18) 3.5 ± 7.0 (11) 2.2 ± 7.2 0.198
6 (15) 23.0 ± 31.7 (11) 0.6 ± 1.2 0.001
9 (13) 14.5 ± 21.4 (14) 0.7 ± 1.9 0.007
12 (12) 9.4 ± 11.3 (14) 0.2 ± 0.4 0.001
* No.  number of subjects tested; L3  infective larvae.
† By Mann-Whitney U test.
TABLE 4
Clearance rates* for Wuchereria bancrofti–infected subjects treated
with single- or multi-dose diethylcarbamazine and albendazole
Time post-treatment No. tested MF/50 L MF uptake Infectivity
3 months
Single 14 7.1 21.4 50.0
Multiple 15 66.7 93.3 100
P† 0.001 < 0.001 0.002
6 months
Single 14 21.4 21.4 21.4
Multiple 12 66.7 66.7 58.3
P† 0.020 0.020 0.105
9 months
Single 14 21.4 21.4 28.6
Multiple 13 84.6 92.3 84.6
P† 0.001 < 0.001 0.003
12 months
Single 14 35.7 57.1 28.6
Multiple 12 75.0 75.0 83.3
P† 0.045 0.429 0.005
* Data shown are percentages of subjects with either total clearance of microfilaria (MF)
by thick blood smear, zero MF uptake by mosquitoes, or zero infective larvae recovered
from mosquitoes.
† Group differences were assessed by chi-square test or Fisher’s exact test.
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We previously reported that MF were sometimes ingested
by Culex mosquitoes that had fed on smear-negative MF car-
riers. However, since very few of the ingested MF developed
to the infective stage, we concluded that low-level and ul-
tralow-level MF carriers are unlikely to sustain filariasis trans-
mission under natural conditions.11 Results in the present
study reinforce this conclusion. Although mosquitoes in-
gested MF from some subjects who had negative MF smears
12 months after DEC/ALB treatment, only 0.2% of mosqui-
toes that fed on such subjects produced L3. This supports the
conclusion in our previous report that the presence of MF in
thick smears in a population is a functional threshold for L3
production and transmission by Culex mosquitoes. Therefore,
we believe that filariasis elimination programs should aim to
reduce MF rates by thick smear to close to zero, but not waste
time and resources trying to detect ultra-low MF carriers by
membrane filtration.
Our study was performed with Cx. pipiens. While it is likely
that similar results would be obtained with other Culex spe-
cies, this should be tested. Results might be very different
with more distantly related mosquitoes. Therefore, we believe
that parallel studies of effects of treatment on MF uptake and
L3 production should be performed with other major filariasis
vector mosquitoes such as Cx. quinquefasciatus and species of
Anopheles and Aedes.
We conclude this report with three points. First, although
our results suggest that mass treatment with single-dose DEC/
ALB (as recommended by GPELF) should greatly decrease
transmission of bancroftian filariasis, multi-dose treatment
was much more effective than single-dose treatment in low-
ering blood MF counts and reducing MF uptake and L3 pro-
duction by mosquitoes. Therefore, we believe that program
managers should consider using a multi-dose DEC/ALB regi-
men for the first round of MDA in filariasis elimination pro-
grams, especially in areas with high baseline infection rates
and intensities. The increased expense and work involved
might be worthwhile if this approach can interrupt transmis-
sion and eliminate filariasis with fewer rounds of treatment
than repeated cycles of single-dose MDA. Second, our study
showed that mosquitoes are very efficient at ingesting MF
from low-count MF carriers. This supports the idea of using
molecular xenodiagnosis as an alternative to blood MF sur-
veys as a means of monitoring progress in filariasis elimina-
tion programs. Third, we strongly believe that more mosquito
research is needed to improve the knowledge base for filari-
asis elimination programs. It is a mistake to focus solely on
filarial parasites in the human host.
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